Catalyst Event

Pfizer Inc (PFE) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

5/30/2026, 12:00:00 AM

OtherSentiment: Positive

Pfizer announced positive Phase 3 TALAPRO-3 trial results on 2026-05-30 for Talzenna plus Xtandi; Medium importance estimated due to significant reduction in disease progression risk.

Korean Translation

화이자가 2026년 05월 30일 3상 TALAPRO-3 임상시험의 긍정적 결과를 발표하였으며, 유의미한 지표 개선으로 중간 수준의 중요도가 예상됨.

Related Recent Events

View Full Timeline